PRESS-RELEASE filed Aug 17, 2026 at 07:00 ET
Fulcrum Therapeutics is being acquired by Slate Medicines in an all-stock reverse merger where pre-merger Fulcrum stockholders will own 5% of the combined company (subject to net cash adjustment) and receive an estimated $270M cash dividend immediately before closing. The combined entity will operate as Slate Medicines (ticker SLTE) and focus on Slate's migraine pipeline, including SLTE-1009, backed by a $245M oversubscribed private placement led by Frazier Life Sciences. For Fulcrum stockholders, this is effectively a liquidation event with a large cash dividend and a small ongoing equity stub in a pre-revenue biotech.